Department of Pharmaceutical Sciences, University of Catania, Catania, Italy.
Drug Dev Ind Pharm. 2011 Jun;37(6):737-46. doi: 10.3109/03639045.2010.539231. Epub 2011 Jan 5.
Solid lipid nanoparticles (SLN) are regarded as interesting drug delivery systems and their preparation techniques have gained a great deal of attention.
To evaluate the feasibility of preparing idebenone (IDE) loaded SLN from O/W microemulsions by the phase-inversion temperature (PIT) method. Since SLN have been proposed to improve drug delivery to the brain, IDE was chosen as model drug due to its activity in the treatment of neurodegenerative diseases.
Cetyl palmitate was used as solid lipid to prepare SLN containing two surfactant/cosurfactant mixtures, isoceteth-20/glyceryl oleate (SLN A) and ceteth-20/glyceryl oleate (SLN B) by the PIT method.
All the formulations tested showed a mean particle diameter ranging from 30 to 95 nm and a single peak in size distribution. Stability tests showed that SLN B were more stable than SLN A. IDE release was dependent both on the type of primary surfactant used and the amount of loaded drug. IDE-loaded SLN were effective in inhibiting 2,2'-azobis-(2-amidinopropane)dihydrochloride (APPH)-induced lactic dehydrogenase (LDH) release and reactive oxygen species (ROS) production in primary cultures of astrocytes obtained from rat cerebral cortex. It is noteworthy that SLN B2 (containing ceteth-20 as primary surfactant and 0.7% w/w IDE) were able to prevent entirely both the LDH release and ROS production induced by APPH.
The PIT method provided SLN with good technological properties. The tested SLN could be regarded as interesting carriers to overcome the blood brain barrier and increase the efficacy of the loaded drug.
固体脂质纳米粒(SLN)被认为是一种很有前途的药物传递系统,其制备技术受到了广泛关注。
评价通过相转变温度(PIT)法从 O/W 微乳液中制备艾地苯醌(IDE)负载的 SLN 的可行性。由于 SLN 被提议用于改善药物向大脑的传递,因此选择 IDE 作为模型药物,因为它在治疗神经退行性疾病方面具有活性。
十六烷醇棕榈酸酯被用作固体脂质,通过 PIT 法制备了两种表面活性剂/助表面活性剂混合物(异十六烷醇-20/甘油油酸酯(SLN A)和十六烷醇-20/甘油油酸酯(SLN B))负载 IDE 的 SLN。
所有测试的配方均显示平均粒径为 30 至 95nm,且粒径分布呈单峰。稳定性测试表明,SLN B 比 SLN A 更稳定。IDE 释放既依赖于所使用的初级表面活性剂的类型,也依赖于负载药物的量。负载 IDE 的 SLN 可有效抑制大鼠大脑皮层原代星形胶质细胞中 2,2'-偶氮双(2-脒基丙烷)二盐酸盐(APPH)诱导的乳酸脱氢酶(LDH)释放和活性氧(ROS)的产生。值得注意的是,SLN B2(含有十六烷醇-20 作为初级表面活性剂和 0.7%w/w IDE)能够完全防止 APPH 诱导的 LDH 释放和 ROS 产生。
PIT 法提供了具有良好技术性能的 SLN。所测试的 SLN 可以被认为是一种很有前途的载体,能够克服血脑屏障并提高负载药物的疗效。